China鈥檚 cervical cancer breakthrough
Print Edition
In a major advance in fighting cervical cancer, a human papillomavirus vaccine developed by Chinese researchers will be widely available in the country for women under 45 in May.
The HPV vaccine was jointly developed by Xiamen University and a subsidiary of YangShengTang Group in southeast China鈥檚 Fujian Province, after an 18-year study. It was approved by the National Medical Products Administration in December 2019.
From next month, the first batch of more than 93,000 vaccines will be available in community hospitals in provincial-level regions including Hubei, Jilin and the Xinjiang Uygur Autonomous Region, said a source of the university yesterday.
Cervical cancer is caused by sexually transmitted infection with certain types of HPV. It is the third most common cancer among women.
China has a very high incidence and death rate, and previous studies show that for Chinese women the peak incidence of HPV infection occurs between 15 and 19.
The World Health Organization and many countries recommend girls get vaccinated between 9 and 14.
The newly available vaccine can protect against HPV 16 and 18, two major HPV types causing 70 percent of all cervical cancer. It can be given to women aged 9 to 45, according to the source.
British pharmaceutical giant GlaxoSmithKline鈥檚 Cervarix is the first HPV vaccine introduced in China and the current market-available vaccine with the same type of coverage. Both vaccines require three shots over six months, but the Chinese vaccine is cheaper. One shot costs 329 yuan (US$46.50). One shot of Cervarix costs 580 yuan.
鈥淢any cervical cancer patients are on low incomes,鈥 said Sui Long, a chief gynecologist at the Obstetrics and Gynecology Hospital affiliated to Fudan University in Shanghai, adding the domestic vaccine will make vaccination affordable for many poor patients.
Vaccines were not available on the Chinese mainland until Cervarix was approved in 2016. Mainland residents had to travel to Hong Kong or abroad instead.
In 2018, the WHO called on all countries to eliminate cervical cancer by 2030. China has been stepping up its efforts.
Another vaccine developed by Xiamen University covering nine HPV types will soon undergo a phase three clinical trial, the last test before release.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
